Bloodwise is attending an advisory board on Tuesday 11th December in London with the pharmaceutical company, Celgene to look at ways of meeting the needs of the blood cancer community with regards to CAR-T therapies.We are hoping to provide them with:
- an understand of the impact and clinical value of CAR T from a patient perspective
- an understand of what information relating to CAR T therapies patient advocacy organisations like Bloodwise require to support their work and meet the needs of patients.
Whilst being aware that very few of our community will have direct experience of CAR-T therapies at this point, it is really important to us that we are able to translate the impact or concerns that our community may have about the future of these therapies so that both Celgene, and ourselves are able to identify need areas and work together to meet these when and where appropriate.
Your thoughts and insights are invaluable and hugely appreciated! Do get in touch if you have any questions on support@bloodwise.org.uk.